Indraprastha Medical Corporation credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

−263	−263	−322	−224	−129	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.36×	−0.36×	−0.54×	−0.47×	−0.34×
−0.94×	−0.99×	−1.32×	−1.16×	−0.85×
37.09×	37.09×	31.89×	37.75×	26.04×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

INDRAMEDCO₹318.30

Indraprastha Medical Corporation Limited

· Pharma & Health

₹ CrorePeersARTEMISMED SHALBY GKSL GPTHEALTH LOTUSEYE DRAGARWQ KMCSHIL KOVAIMcap ₹2,918 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Net Debt	-128.8	-224.4	-321.8	-263.3	-263.3
Net Debt/Equity	-0.34	-0.47	-0.54	-0.36	-0.36
Net Debt/EBITDA	-0.85	-1.16	-1.32	-0.99	-0.94
Interest Coverage (EBIT/Interest)	26.04	37.75	31.89	37.09	37.09

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.